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Abstract
Background:  Clinical case treatment of malaria infections where Plasmodium falciparum and
Plasmodium vivax are sympatric has achieved effective reductions in P. falciparum prevalence and
incidence rates, but has been less successful for P. vivax. The high transmissibility of P. vivax and its
capacity to relapse have been suggested to make it a harder parasite species to control.
Methods: A clinical malaria case treatment programme was carried out over a decade in a Karen
community composed of seven hamlets on the Thai-Myanmar border.
Results: From 1994 to 2004, prevalence rates of both P. falciparum and P. vivax decreased by 70–
90% in six of the seven study hamlets, but were unchanged in one hamlet. Overall, incidence rates
decreased by 72% and 76% for P. falciparum and P. vivax respectively over the period 1999–2004.
The age-incidence and prevalence curves suggested that P. vivax was more transmissible than P.
falciparum  despite a greater overall burden of infection with P. falciparum. Male gender was
associated with increased risk of clinical presentation with either parasite species. Children (< 15
years old) had an increased risk of presenting with P. vivax but not P. falciparum.
Conclusion:  There was a considerable reduction in incidence rates of both P. vivax and  P.
falciparum over a decade following implementation of a case treatment programme. The concern
that intervention methods would inadvertently favour one species over another, or even lead to
an increase in one parasite species, does not appear to be fulfilled in this case.
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Background
Over the last decade in Thailand, a concerted programme
at the national level of clinical case treatment coupled
with vector control programmes has led to a greatly
reduced burden of malaria [1], restricting malaria trans-
mission to the border provinces. The Tak Malaria Initia-
tive (TMI) sought to address the malaria problem in one
of these border provinces, Tak, implementing a system of
early diagnosis and treatment with mefloquine-artesunate
combination therapy [2]. This initiative proved most suc-
cessful in reducing morbidity and mortality of P. falci-
parum  but had seemingly little impact on P. vivax.
Plasmodium vivax accounts for over half of all malaria
infections outside Africa and in 2002 the Multilateral Ini-
tiative on Malaria convened a special conference, "Vivax
Malaria Research: 2002 and Beyond" [3]. The conference
highlighted the disparity of knowledge and research effort
concerning these two major malaria parasite species and
called for increased effort to readdress this situation,
including improving comprehension on the epidemiol-
ogy of P. vivax.
Outside Africa, P. falciparum often coexists with P. vivax,
and as noted above in the TMI, there have been many
cases where P. vivax prevalence has remained unchanged,
or even increased, despite a drop in P. falciparum [4,5].
This outcome goes against general predictions that current
principle intervention strategies would have a greater
impact on P. vivax than P. falciparum [6]. The reasons for
such species-specific patterns are unclear and both mos-
quito and drug treatment explanations have been invoked
[7,8]. It has been suggested that the biology of P. vivax
makes it a harder species to control and one that will
require a different strategy to that of P. falciparum [7]. The
existence of exo-erythrocytic hypnozoite stages enables P.
vivax to avoid drugs targeting blood stage parasites. Plas-
modium vivax gametocytes are produced at very early
stages of blood infection, even directly from hypnozoites
and thus may enable transmission to mosquitoes before
any drug treatment is delivered. The sporogonic develop-
ment of P. vivax within the mosquito is the fastest of all
malaria spp. infecting humans [9], taking on average 11
days to complete. Such differences may indeed enable P.
vivax to be less affected by an intervention strategy target-
ing P. falciparum, but do not explain its observed increases
in prevalence in areas sympatric for P. falciparum and P.
vivax.
Increased prevalence of P. vivax has been noted especially
in Thailand, increasing from 20% to 50% of cases over the
last forty years [7]. Two major lines of argument have
been used to explain this. Firstly it has long been recog-
nized that there is competitive interaction between the
two species within the human host during a co-infection
[10-12]. It has more recently been suggested that the two
species may negatively impact upon one another through
the development of cross-species immunity [6] and there
is evidence for species-transcending parasite density-
dependent immune responses [13,14]. Thus, specifically
targeting one species may release the other from competi-
tive suppression. Indeed, emergence of a second species
following drug clearance of the apparent species infection
is well known [15,16]. Secondly, mosquito vector species
may differ in their vectorial competence and capacity for
P. falciparum and  P. vivax [4,17,18]. Environmental
changes that alter vector species composition could have
a profound impact on parasite species abundance.
The relative contribution of these factors to the changing
pattern of species abundance is difficult to ascertain and
likely to be highly dependent on study site. However, it is
clear that in order to develop appropriate intervention
strategies to target both P. falciparum and P. vivax requires
improved knowledge on basic P. vivax epidemiology. If, as
has been suggested, the two parasite species impact upon
each other when in co-existence, epidemiological studies
need to consider both species simultaneously. This study
reports on the basic epidemiological patterns of P. falci-
parum and P. vivax in a Karen community in Thailand on
the border with Myanmar followed for a decade and
receiving case treatment.
Methods
Study population and site
The study was conducted in a mountainous area of Suan
Phung district, Ratchaburi province, Thailand (Figure 1).
Suan Phung is a small district situated near the Thai-
Myanmar border surrounded by the long Tanaosri ranges
on the western side. The Tanaosri subdistrict is located at
the southern part of Suan Phung, approximately 163 km
west of Bangkok. Suan Phung currently has a population
of 5,368, has been growing in population number over
the last decade and is made up of a group of four closely
related ethnic groups, the majority of which are Karen
(85%), some Thai (14%) and the rest Mon and Burmese
(1%). The majority of the both male and female labour
forces are hunters-gatherers with limited agricultural prac-
tice. A census of the population was carried out in 1994/
5, 1998, 2001 and 2004. Overall, a total of 3,484 villagers
of all ages (Table 1) living in seven hamlets were recruited
for the study (Figure 1). An initial survey during the 1994/
5 census recruited 1,104 individuals and this number was
increased to 1,469 by the 1998 census, 3,079 by the 2001
census and 3,484 by the 2004 census. Individuals wishing
to participate in the study were recruited at each census
and between times by presentation at the clinic. The
project protocol and objectives were explained to the pop-
ulation and informed consent was individually obtained
from all study participants or their parents. Ethical per-
mission for the study was granted by the Ethical Commit-Malaria Journal 2008, 7:99 http://www.malariajournal.com/content/7/1/99
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tee of the Ministry of Public Health of Thailand. In this
study site, the only two mosquito vector species are Anoph-
eles minimus and Anopheles maculatus, which are present
throughout the year and are predominantly exophagic
[18]. The rainy season occurs from June to September.
Although bed nets have been promoted, their use remains
limited; reliable information on their regular use was
obtained from only 726 individuals.
Data collection
Both active and passive case detection methods were used
to collect the data. Two cross-sectional serial surveys were
carried out, in 1994–5 and in 2003–4 and the incidence
of malaria was measured from June 1998 to February
2005 in a health centre constructed for the site.
Active case detection
In order to determine the prevalence of malaria, a malaria
survey (thick and thin smears) was carried out every
month from June 1994 to May 1995, covering a popula-
tion of 1,104 individuals in the seven hamlets. A second
cross-sectional survey was carried out every 45 days from
June 2003 to May 2004 in all hamlets, covering 2,663 sub-
jects who agreed to participate.
Passive case detection
Clinical malaria episodes were defined as the presence
fever (axillary temperature > 37.5°C) or fever-related
symptoms including headache, back pain, chills, myalgia,
nausea, and vomiting associated with a slide positive for
blood-stage asexual or sexual P. falciparum, P. vivax, Plas-
modium malariae and Plasmodium ovale parasites at any
density. To determine the correct number of independent
clinical episodes, individuals presenting on consecutive
occasions with blood-stage malaria parasite of the same
species within 30 days (and also 90 days for P. vivax) after
treatment of the initial infection were excluded from the
analysis. The 30- and 90-day criteria were set to make sure
that the most recent episode of malaria is a new one and
not from a previous infection. Relapse rate of vivax in
Thailand is quite high (even if drug compliance and treat-
ment completion is high) and it is thus questionable to
assume that an episode 30 days after a previous vivax
infection is a new one; hence we additionally analyse
using a 90-day exclusion time. On the other hand, since
the drug regimen for falciparum malaria is more effica-
cious, 30 days is sufficient to rule out recrudescence. The
"unexcluded" incidence rates were additionally provided.
Individuals presenting on consecutive occasions with
non-malaria fever (or aforementioned symptoms) within
seven days following first presentation were likewise
excluded from analyses. In addition, initial parasite nega-
tive visits were excluded if followed by a parasite-positive
visit within the following two days. All positive malaria
cases were treated with appropriate antimalarial treatment
according to the recommendation of the Malaria Divi-
sion, Ministry of Public Health. Subjects diagnosed with
Geographical localisation of study site Figure 1
Geographical localisation of study site. (A) Ratchaburi 
in Thailand. (B) Suan Phung in Ratchaburi province and (C) 
Hamlets and health centre in study.
Ratchaburi
A B
C Health
Centre
Hamlet 1
Hamlet 2
Hamlet 7
Hamlet 6
Hamlet 5
Hamlet 4
Hamlet 3
Table 1: Age and sex distribution of the population studied at the 
time of the 2004 census.
Age N male female
< 1 33 19 14
1–4 462 241 221
5–9 510 262 248
10–14 455 224 231
15–24 730 357 373
25–39 740 362 378
40–59 428 218 210
≥ 60 126 54 72
Total 3484 1737 1747Malaria Journal 2008, 7:99 http://www.malariajournal.com/content/7/1/99
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having P. falciparum were treated with a single dose of 250
mg mefloquine tablets and primaquine depending on age
(Table 2a) and, when diagnosed positive for P. vivax,
treated with chloroquine (250 mg) and primaquine for
four days following the schedule in Table 2b. Self-treat-
ment is considered to be rare in the study area, because the
only other access to treatment is a government clinic with
which the study has good communication concerning
malaria treatment of the study site population. Early treat-
ment failure (ETF) and Late treatment failure (LTF) were
defined as presentation with the same malaria species
within seven days and seven to 30 days post-treatment,
respectively.
In all cases parasite positivity was established as follows.
Thick and thin blood films were prepared and stained by
3% Giemsa. Blood films were examined under an oil
immersion objective at × 1,000 magnification by the
trained laboratory technicians and 200 thick film fields
were examined before films were declared negative. Para-
site species were identified on thin films and densities
(per μl) were calculated from thick film by establishing
the ratio of parasites to white blood cells (WBC) after at
least 200–500 WBCs had been counted and then multi-
plying the parasite count by 8,000, the average WBC count
per  μl of blood. Asexual and gametocyte stages were
recorded separately.
Data and statistical analyses
Statistical analyses and model fitting were conducted
using the statistical package Genstat 7.1.
Cross-sectional study analyses (active case detection in 1994 and 
2004)
Factors affecting prevalence rates of both P. falciparum and
P. vivax and changes over time were analysed by fitting a
GLMM (Generalised Linear Mixed Model) with binomial
error structure. Individual person was fitted as a factor in
the random model to take into account repeated samples
from the same individual. The cross-sectional surveys
(1994 and 2004) were first analysed separately and then
together. Hamlet (7), gender (male/female) and age (< or
≥ 15 years old) were fitted as explanatory variables and
model fitting proceeded by progressively removing non-
significant factors from the full model that included all
possible variable interaction terms. Inclusion of such
interaction terms was considered important as it has been
reported on numerous occasions that gender and age-spe-
cific behaviour can influence exposure and this can vary
locally depending on the nature of the environment. Age
was additionally fitted as a factor with eight groups (< 1,
1–4, 5–9, 10–14, 15–24, 25–39, 40–59 and 60+ years of
age), and as a continuous variable, but both proved less
explanatory (lower adjusted r2) than age defined as < or ≥
15 years old. Because the data were over-dispersed a dis-
persion parameter was estimated. Wald statistics, which
approximate to a χ2 distribution, were established. Odds
ratios with 95% confidence intervals (CI95%) are given.
Clinical case analyses (passive case detection)
Factors influencing incidence rates and parasite density of
either P. falciparum or P. vivax were analysed by fitting a
GLMM with a Poisson error structure. Individual person
Table 2: Drug treatment schedules and doses
(a) P. falciparum
Patient group Mefloquine (250 mg tablet) Primaquine (mg)
< 1 year 1/2 -
1–3 years 3/4 5
4–8 years 1 1/2 10
9–14 years 2 15
15+ years 3 30
(b) P. vivax
Patient group Day 1 Day 2 Day 3 Day 4
C* C* C* P+ C* P+ C* P+ C* P+
< 6 m 1/2 - - - 1/2 - - - - -
6 – 1 1  m 1 - - -1 / 211 / 2- - -
1–3 y 1 1 - 2.5 1 2.5 1 2.5 1 2.5
4 – 8  y 1 1 151515 15
9–14 y 2 2 - 10 1 10 1 10 1 10
1 5 + y 2 2 21 521 521 5 2 1 5
m – months; y – years; C – chloroquine phosphate (250 mg); P – primaquine; * - tablet; + - mgMalaria Journal 2008, 7:99 http://www.malariajournal.com/content/7/1/99
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was fitted as a factor in the random model to take into
account repeated presentations from the same individual.
Factors include year (1999–2004), month (12), hamlet
(7), and gender, with age factored into two groups (< 15
and ≥ 15 years of age). Initially a full model including age-
gender-hamlet interactions was fitted and then the model
was refined to include only statistically significant param-
eters and interactions. The seasonality of transmission in
this region varies annually and thus month was consid-
ered only via its interaction with year. Because the data
were over-dispersed a dispersion parameter was esti-
mated. Wald statistics, which approximate to a χ2 distribu-
tion, were established. The effect of bed net use was
analysed using the reduced data set (N = 726), incorporat-
ing bed net use as an extra explanatory factor and analysed
as above. Relative Risk with CI95% is given.
Spearman's Rank correlation was used to establish the
correlation between the monthly numbers of cases of P.
vivax (or P. falciparum) that occurred within 90 days fol-
lowing treatment of P. falciparum (or P. vivax) with the
numbers of cases of P. vivax (or P. falciparum) occurring
independently of treatment.
Attributable fraction
A clinical case of malaria is often diagnosed if the individ-
ual presents with fever, headache or other symptoms asso-
ciated with malaria (such as chills, pains etc) and has a
positive blood slide. The fraction of fevers (or other
malaria-associated symptoms) attributable to malaria can
be simply calculated as   where Pf is the pro-
portion of fevers with parasites present and Pa the propor-
tion of asymptomatic but parasite positive individuals,
sampled from the general population. However, in areas
endemic for malaria, the proportion Pa may be very high
and thus an alternative formula is widely used where
 where Odds Ratio Pf:Pa is the
proportion of odds of having parasites with fever over
having parasites without fever [19]. Here using the cross-
sectional survey performed in 2003–2004, with clinical
case data from the corresponding period, the proportion
of clinical presentations with malaria was compared with
the calculated attributable fraction.
Results
Active case detection: changes in gross prevalence rates 
over the decade of intervention
In the cross-sectional study in 1994, a total of 9,417 slides
were read from 1,104 individuals for whom complete
information on age, gender and hamlet were available.
Plasmodium falciparum prevalence rates varied seasonally
from 0.5% in February to 7% in June, varied among ham-
lets (P < 0.001) (Figure 2a) and were higher in males than
females (3.41% vs. 1.95%) (OR = 1.90 [CI95% 1.43–2.37]
P = 0.003). However, there was a significant gender-age
group interaction whereby adult males (≥ 15 years old)
had higher prevalence rates than male children (< 15 years
old), whereas adult females had lower prevalence rates
than female children (P < 0.001). Analysing by gender
revealed that although female children had increased
odds of being infected with P. falciparum (OR = 1.50
[CI95% 1.09–2.41] P = 0.035), male children did not in
fact have significantly lower odds of infection than adult
males (OR = 0.71 [CI95% 0.54–1.04] P = 0.093). For P.
vivax, by contrast, prevalence rates were significantly
higher in the children irrespective of gender (OR = 2.89
[CI95% 2.30–3.89] P < 0.001); gender was however impor-
tant per se with males having a slightly higher prevalence
rate than females (1.75% vs. 1.06%; OR = 1.74 [CI95%
1.31–2.16] P < 0.001). P. vivax prevalence rates again dif-
fered significantly among hamlets (P < 0.001) (Figure 2b).
Seasonal variation in prevalence rates was less marked for
P. vivax, varying from 1.4% in February to 4.5% in May.
Age-prevalence profiles differed between the parasite spe-
cies, where peak prevalence of P. vivax occurred at 5–9
AF
Pf Pa
Pa
=
−
− 1
AF P OddsRatioPf Pa f =− × 1 1
:
Schematic diagram of (A) P. falciparum and (B) P. vivax gross  prevalence rates and (C) Percentage drop in gross preva- lence rates in seven hamlets in Suan Phung following a decade  of clinical case treatment Figure 2
Schematic diagram of (A) P. falciparum and (B) P. 
vivax gross prevalence rates and (C) Percentage drop 
in gross prevalence rates in seven hamlets in Suan 
Phung following a decade of clinical case treatment. 
Connecting lines are illustrative rather than indicative of any 
linear relationship. Hamlet code: 1: Blue diamond , 2: Pink 
square  , 3: Yellow triangle  , 4: Light blue cross ×, 5: Pur-
ple star *, 6: Brown circle l, 7: Green plus +.
           (A)                (B) 
0
1
2
3
4
5
6
7
8
P
a
r
a
s
i
t
e
 
P
r
e
v
a
l
e
n
c
e
 
R
a
t
e
 
(
%
 
s
l
i
d
e
s
 
p
o
s
i
t
i
v
e
 
o
v
e
r
 
a
 
y
e
a
r
)
1994 2004
0
1
2
3
4
5
6
7
8
1994 2004
-30
-10
10
30
50
70
90
P
e
r
c
e
n
t
a
g
e
 
d
r
o
p
 
i
n
 
p
a
r
a
s
i
t
e
 
s
p
e
c
i
e
s
 
p
r
e
v
a
l
e
n
c
e
 
r
a
t
e
s
falciparum vivax
(C) Malaria Journal 2008, 7:99 http://www.malariajournal.com/content/7/1/99
Page 6 of 11
(page number not for citation purposes)
years old with a rapid decline after 14 years of age,
whereas P. falciparum prevalence rates increased steadily
to a peak at 15–24 years old (Figure 3). There were 31 P.
malariae and one P. ovale positive slides. There were 16
mixed infections of P. falciparum-P. vivax, 2 mixed infec-
tions of P. falciparum-P. malariae and 1 of P. malariae-P.
vivax.
In 2004, a total of 13,721 slides were read from 2,663
individuals. Plasmodium falciparum prevalence rates still
varied among hamlets (P < 0.001) (Figure 2a) and were
higher in males vs. females (0.98% vs. 0.33%) (OR = 2.58
[CI95%  2.26–2.90] P < 0.001) and children vs. adults
(0.97% vs. 0.70%) (OR = 2.86 [CI95% 2.52–3.29] P <
0.001). There was, however, no longer any gender-age
interaction. For P. vivax, there remained significant varia-
bility among hamlets (P = 0.003), largely due to hamlet 2
(Figure 2b) and significantly higher rates in children than
adults (0.70% vs. 0.07%) (OR = 8.71 [CI95% 7.30–10.79]
P < 0.001). Males and females, however, did not differ
(0.5% vs. 0.29%)(P = 0.14). Seasonal variation was like-
wise less marked, varying from 0.1% in April to 1.5% in
June for P. falciparum and from 0.2% to 0.6% for P. vivax.
Age-prevalence profiles similarly levelled off across age
groups, although P. vivax prevalence remained concen-
trated in the < 15 year olds (Figure 3). There were no pos-
itive slides for P. malariae or  P. ovale and no mixed
infections.
As evident from Figure 2c, gross prevalence rates of both
P. falciparum and P. vivax decreased over the decade by
70–98% (P < 0.001 for both species) in six of the seven
hamlets. Hamlet 2, however, showed only a small
decrease in P. falciparum prevalence rates (32%) and a
28% increase in P. vivax prevalence rates. These changes in
hamlet 2 were not significant (P. falciparum P = 0.59; P.
vivax P = 0.69); notably only 20 individuals in hamlet 2
participated in the 1994 study compared with 209 in the
2004 study.
Passive case detection: incidence rates
From 1999 to 2004 (six years) there were 17,454 inde-
pendent clinical presentations by 2,515 individuals
(Range 1–47 per person; mean 6.9 and median 5). Of
these 2,136 were positive for P. falciparum, presented by
1,048 individuals (Minimum of 1 and a maximum of 13
positive presentations per person; mean 2.0 and median
1). Fever (94% of all malaria parasite positive infections)
and headache without fever (3.3%) were associated with
the majority of infections with P. falciparum. There were
1,142 cases of P. vivax (948 cases using the > 90 day novel
infection criterion), presented by 582 individuals (Mini-
mum of 1 and a maximum of 12 positive presentations
per person; mean 2.0 and median 1). In addition there
were 28 cases of P. malariae and five cases of P. ovale. Fever
(95.3% of all positive infections) and headache without
fever (2.1%) were associated with the majority of infec-
tions with P. vivax. A total of 3,246 infections by any
malaria parasite spp. were presented by 1,298 individuals
at any time over the period of study. Some 332 individu-
als had independent infections of both P. falciparum and
P. vivax, 250 were only ever infected with P. vivax and 716
only ever with P. falciparum. Only 32 P. falciparum – P.
vivax and three P. falciparum – P. malariae mixed infections
were observed. Over all hamlets incidence rates for clini-
cal cases positive for P. falciparum decreased from 248
(CI95% 122–374) per 1,000 person-years in 1999–2001 to
69 (CI95% 47–92) in 2002–2004 and for P. vivax rates
decreased from 139 (CI95% 65–214) to 33 (CI95% 19–46).
Exclusion of repeated presentation within 30 days led to
the exclusion of 474 cases of P. falciparum and 18 cases of
P. vivax (194 cases using the > 90 day novel infection cri-
terion). There was a clear decrease in this number from
year 2002 for P. falciparum (1999–2001 Mean 103 CI95%
91–115 vs. 2002–2004 Mean 55 CI95% 43–67). Incidence
rates using the full "unexcluded" data set were 300 (CI95%
Age-specific prevalence rates of P. falciparum and P. vivax in  1994 (light blue) and 2004 (purple) Figure 3
Age-specific prevalence rates of P. falciparum and P. 
vivax in 1994 (light blue) and 2004 (purple). Shown are 
the weighted mean (± 95% Confidence intervals) percentage 
of each age group infected during cross-sectional surveys in 
1994 and 2004 across the seven study hamlets.
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148–452) per 1,000 person-years in 1999–2001 and 86
(CI95% 59–113) in 2002–2004 for P. falciparum and for P.
vivax  the incidence rates were 142 (CI95% 66–218) in
1999–2001 and 33 (CI95% 20–47) in 2002–2004. There
were eight cases of P. falciparum ETF and 78 cases of LTF.
There were no cases of treatment failure for P. vivax.
There was distinct seasonality in clinical cases with annual
peaks from April to June (Figure 4). Plasmodium falciparum
clinical cases peaked annually in May, accounting for 17–
39% of the total number of annual cases. The annual peak
of clinical P. vivax cases in May was apparent but less
marked, but still accounted for 10–25% of annual cases.
Examination of infections of one species following treat-
ment of another, revealed only 19 cases of P. vivax within
30 days following treatment of P. falciparum and 16 cases
of P. falciparum following treatment of P. vivax. Extending
this period to 90 days revealed 87 cases of P. vivax occur-
ring following treatment of a P. falciparum case and 47
cases of P. falciparum occurring after treatment of P. vivax.
This number decreased from 37 and 55 in 1999–2000 to
4 and 6 in 2003–4 for P. falciparum and P. vivax, respec-
tively. In an attempt to determine the likelihood that
these "90-day post-treatment" cases arose from emerging
co-infections rather than novel infections, their distribu-
tion over time was compared to that of novel "independ-
ent" cases by Spearman's Rank correlation. Although there
was significant correlation between the distribution of
post-treatment and novel "independent" cases (P. falci-
parum P < 0.001; P. vivax P < 0.001), correlation coeffi-
cients of P. vivax (post-treatment vs. "novel") and P.
falciparum  (post-treatment vs. "novel") were only 0.45
and 0.56 respectively. By comparison, the correlation
coefficient between P. vivax and P. falciparum novel cases
was 0.75.
As with the cross-sectional studies, there was considerable
variation in incidence rates among hamlets, being highest
for both species in hamlet 2. Male gender was associated
with increased risk of clinical presentation with either P.
falciparum (RR = 1.42 [CI95%1.34–1.52] P < 0.001) or P.
vivax (RR = 1.24 [CI95%1.16–1.33] P < 0.001). Children
(aged < 15 years old) had an increased risk of presenting
with P. vivax over adults (RR = 2.86 [CI95% 2.63–3.12] P <
0.001), but not so for P. falciparum (P = 0.32). More
detailed age-specific incidence rates showed that, as found
in the cross-sectional surveys, peak incidence occurred in
younger age groups (one to nine years old) for P. vivax
than for P. falciparum (5–14 years old) (Figure 5). By 2003
age-specific differences in incidence rates became negligi-
ble for either species. Bed nets were not found to have sig-
nificant impact on either P. falciparum (P = 0.059) or P.
vivax (P = 0.86) incidence rates.
There was good concordance in the proportion of fevers
that were found to be positive for malaria parasites and
the fraction of fevers attributable to malaria as calculated
using two methods that incorporate cross-sectional survey
data (Table 3). This suggests that a large majority of infec-
tions lead to febrile episodes and that the proportion of
infections that are asymptomatic is very small.
Parasite density and gametocyte parasite stages
Peak P. falciparum trophozoite densities were observed in
one to nine year olds (55,409 ± 4,825 parasites/μl) and
decreased steadily with age to level off in the > 25 year
olds (12,402 ± 1,418 parasites/μl). P. vivax asexual para-
site densities were lower than those of P. falciparum (8,105
± 412 parasites/μl vs. 36,927 ± 2,419). Densities peaked
Summary of the total number of monthly clinical presenta- tions, those positive for P. falciparum and those positive for P.  vivax from Jan 1999 to Dec 2004 Figure 4
Summary of the total number of monthly clinical 
presentations, those positive for P. falciparum and 
those positive for P. vivax from Jan 1999 to Dec 2004. 
Background colour shading delimits year.
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in the 0–9 year olds (9,264 ± 548 parasites/μl) but
decreased only slowly with age (> 25 years old 4116 ± 711
parasites/μl). For either species there were no differences
among hamlets and densities oscillated over the years
with an increase from 1999 to 2002 and then decreasing.
Of the 2,101 clinical presentations positive only for P. fal-
ciparum, 84 had gametocytes whereas of the 32 mixed P.
falciparum-P. vivax infections only one had P. falciparum
gametocytes and 10 had P. vivax gametocytes. Of the
1,110  P. vivax single infections 324 had gametocytes.
There was thus no discernable effect of mixed infections
on gametocyte production for either P. falciparum (P =
0.48) or P. vivax (P = 0.96). The proportion of P. falci-
parum  and  P. vivax infections with gametocytes was
strongly affected by age: Children (< 15) had higher odds
of having detectable gametocytes than adults (P. falci-
parum OR = 3.11 [CI95% 2.37–4.52] P < 0.001; P. vivax OR
= 1.56 [CI95%1.12–2.58] P = 0.02). The proportion of
infections with gametocytes did not change over time. A
mean of 35% (CI95% 29–40%) of P. vivax infections had
gametocytes over the six years and 6.4% (CI95% 4.1–8.5%)
of P. falciparum infections had gametocytes. Plasmodium
vivax gametocyte densities were higher than those of P. fal-
ciparum  (670/μl [CI95% 550–790]  vs. 332 [CI95%  181–
483]).
Discussion
Over the decade from 1994–2004 there was a considera-
ble reduction in both P. falciparum and P. vivax prevalence
rates in this Karen community. In contrast to many
reports on the consequences of clinical case treatment for
relative parasite species composition [2,4,5], there were
similar reductions in the prevalence rates of both P. vivax
than P. falciparum (Figure 2c). Drug treatment in all cases
followed the national guidelines and was specific to each
parasite species. The absence of treatment failures for P.
vivax suggests that drug resistance has not developed to
chloroquine and primaquine, as has generally been found
to be the case in Thailand over this period of study [20].
No changes in malaria mosquito vectors were observed in
the study area, with An. minimus and  An. maculatus
remaining the only two vectors. Bed nets (unimpreg-
nated) had, as elsewhere described in Thailand [21], little
impact on incidence rates, most likely reflecting the
exophilic behaviour of the mosquito [22].
This study provided an insight into key epidemiological
parameters of both P. falciparum and P. vivax and how
they changed with an overall decrease in malaria. In addi-
tion, several risk factors pertinent to the epidemiology of
both P. falciparum and P. vivax were identified and notably
these risk factors were not identical for both species. The
majority of infections seemingly lead to a symptomatic
episode, permitting comparison of data from the cross-
sectional surveys and the clinical case detection. The clin-
ical case study and the 1994 initial survey revealed that
male gender was a risk factor for both P. falciparum and P.
vivax. This risk was lost for P. vivax in 2004, most probably
because of the greatly reduced burden of P. vivax infection
and the relatively small risk previously incurred. Gender
has been previously identified as a risk factor for P. falci-
parum infection in Thailand [21], where it was suggested
to reflect an increased exposure to infection associated
with adult male tendency to be active outdoors in the
evening. Here the effect of gender was less important,
which might reflect the absence of Anopheles dirus, a forest-
dwelling mosquito that is a better vector than An. minimus
or An. maculatus. Young age (here considered < 15 vs. ≥ 15
years old) incurred a considerable risk for P. vivax infec-
tion in both cross-sectional surveys and in clinical presen-
tation. By contrast age did not incur a risk for P. falciparum
infection except in the 2004 cross-sectional study.
Paradoxical parasite species-specific age-profiles for sym-
patric  P. falciparum and  P. vivax have been repeatedly
Table 3: Proportion of fevers positive for malaria compared with the fraction of fevers (and 95% confidence intervals) attributable to 
malaria in individuals less than and greater than 15 years old, calculated by Method 1:   and Method 2: 
. Pf is the proportion of fevers with parasites and Pa the proportion of asymptomatic but parasite positive individuals. 
Age (years) Propn. fevers malaria positive AF – Method1 AF – Method2
Pfal
< 15 0.104 0.086 (0.072–0.103) 0.101 (0.098–0.103)
≥ 15 0.101 0.089 (0.072–0.11) 0.099 (0.097–0.100)
Pviv
< 15 0.051 0.041 (0.031–0.053) 0.048 (0.045–0.050)
≥ 15 0.028 0.025 (0.016–0.038) 0.028 (0.027–0.028)
AF: Attributable Fraction. Pfal: Plasmodium falciparum; Pviv: Plasmodium vivax. See Methods for details.
AF P OddsRatioPf Pa f =− × 1 1
:
AF
Pf Pa
Pa
=
−
− 1Malaria Journal 2008, 7:99 http://www.malariajournal.com/content/7/1/99
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noted [21,23,24], where peak prevalence and incidence of
P. vivax occurs at an earlier age than for P. falciparum
despite higher overall rates of P. falciparum. A lower aver-
age age of first infection would indicate that P. vivax is
more transmissible and many features of its biology, most
especially those involved in transmission to the vector
(gametocyte productivity and duration of sporogonic
development), would enable this. In addition, some evi-
dence suggests that α+-thalassemia individuals are more
susceptible to P. vivax, but protected from severe P. falci-
parum disease and that thus there may be some cross-spe-
cies immunity [6,25]. Early age infection by P. vivax may
thus reduce disease and infection rates due to P. falci-
parum. Here, peak rates of P. vivax occurred in the one to
nine year olds until 2004, at which time rates were very
low and imperceptibly different among the young age
groups. P. falciparum prevalence rates decreased from the
age of 25 year olds in 1994, then stabilized out at a peak
in the 5–14 year olds until 2004 at which time rates
became concentrated in the < 15 year olds. How to
explain this apparent paradox of P. vivax imposing a lower
burden of disease and yet predominately occurring in
younger age groups than P. falciparum in a setting where
there the proportion of asymptomatic infections for either
species is very small. The proposed biological features
making P. vivax more transmissible are evident here and
α+-thalassemia occurs at a high frequency in this region.
The proportion of infections with detectable gametocytes
was five times higher for P. vivax than for P. falciparum and
the gametocyte density considerably higher despite lower
asexual densities. Moreover, that children had an
increased risk of having infections with gametocytes for
both species would be of greater significance for P. vivax
where age was found to incur an increased risk of infec-
tion. Such transmission and infection advantages would
be compatible with the observed younger infection age
profile for P. vivax, and yet overall incidence rates are
lower than for P. falciparum. This observed difference,
however, may belie the actual relative abundance of the
two species and a crucial contributing factor may be the
suppressive effect of P. falciparum in a co-infection.
Several recent articles have provided an excellent review of
the importance of mixed infections and their likely under-
estimation, especially in Thailand [26-28]. The capacity of
one Plasmodium species to suppress another within the
human is to some extent dependent on the infection sta-
tus of each species, where both P. falciparum and P. vivax
can dominate the infection. However, P. falciparum gener-
ally dominates when present [11,12]. Misdiagnosis of
cryptic mixed infections as single species infections has
obviously important consequences for establishing preva-
lence rates. Although PCR has to some extent improved
capacity to detect cryptic infections, P. vivax may remain
latent as hypnozoite stages in the liver until the P. falci-
parum infection has been cleared. Here, there were a large
number of P. vivax cases that occurred following treat-
ment of P. falciparum, as has been previously found in
Thailand [15]. A lesser number of P. falciparum cases fol-
lowed treatment of P. vivax infections. Unequivocally dis-
tinguishing novel from latent infections in this study site
of seasonally variable but perennial transmission is not
possible with the current study design. However, simple
Age-specific malaria incidence rates (light blue P. falciparum;  purple P. vivax) Figure 5
Age-specific malaria incidence rates (light blue P. fal-
ciparum; purple P. vivax). Shown are the weighted mean 
(± 95% Confidence intervals) number of clinical presenta-
tions per person-year in each age group infected across the 
seven hamlets in 1999, 2001 and 2003.
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analysis showed that there was worse correlation between
the monthly incidence of post-treatment and independ-
ent infections for each species than between independent
infections of either species. Notably the correlation was
poorest for P. vivax (independent vs. post-treatment). This
would be consistent with at least a proportion of such
post-treatment P. vivax infections being latent and not
novel infections.
Patterns of reciprocal seasonality in parasite spp. rates
have been interpreted as additional suggestive evidence
for antagonistic interaction [24]. Such patterns are not,
however, consistently found and will certainly depend on
vector species activity. In this study peak incidence
occurred in May for both species and accounted for a sig-
nificant proportion of total annual disease incidence.
Despite the overall low force of infection, such strong sea-
sonality would increase considerably the possibility of
concomitant inoculation of both species and thus the
potential for antagonistic interaction. Both experimental
infection and epidemiological studies suggest that P. falci-
parum has a greater suppressive potential [6,11,12,29] and
the data in this study are consistent with this. Thus, the
greater potential for transmission by P. vivax may in fact
result in a greater number of infections, but which do not
materialize as patent infections until later, if at all; it has
been estimated that only 60% of P. vivax infections
relapse in Thailand [16]. When delayed patency occurs, it
is likely to be at a time less propitious for transmission.
Such temporal heterogeneity in transmission intensity
may be alleviated by non-overlapping spatial distribution
of the parasite species, which can occur even at very local
scales [30,31]. Only small differences in relative parasite
species rates were, however, observed among the seven
hamlets.
Conclusion
In conclusion, in this study site where a programme of
passive case detection and treatment of both P. vivax and
P. falciparum was put into place, there has been a consid-
erable reduction in incidence rates over a decade. The con-
cern that intervention methods would inadvertently
favour one species over another [6,7], or even lead to an
increase in one parasite species, does not appear to be ful-
filled in this case.
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